Nordea Investment Management AB Acquires 465 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Nordea Investment Management AB boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,996 shares of the company’s stock after buying an additional 465 shares during the quarter. Nordea Investment Management AB’s holdings in Neurocrine Biosciences were worth $3,435,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of NBIX. Acadian Asset Management LLC purchased a new position in Neurocrine Biosciences in the fourth quarter valued at $32,000. Quadrant Capital Group LLC increased its holdings in Neurocrine Biosciences by 9,242.9% in the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after buying an additional 647 shares during the last quarter. Arbor Wealth Management LLC purchased a new position in Neurocrine Biosciences in the fourth quarter valued at $92,000. SG Americas Securities LLC grew its holdings in shares of Neurocrine Biosciences by 8.7% during the fourth quarter. SG Americas Securities LLC now owns 1,971 shares of the company’s stock worth $141,000 after purchasing an additional 157 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Neurocrine Biosciences by 75.2% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,120 shares of the company’s stock worth $151,000 after purchasing an additional 910 shares during the last quarter. 95.86% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Eric Benevich sold 5,835 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $87.44, for a total transaction of $510,212.40. Following the sale, the insider now owns 14,910 shares in the company, valued at $1,303,730.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Haig P. Bozigian sold 34,547 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $75.51, for a total transaction of $2,608,643.97. The disclosure for this sale can be found here. Over the last three months, insiders have sold 175,155 shares of company stock valued at $14,142,477. Company insiders own 4.30% of the company’s stock.

NBIX has been the subject of several recent research reports. Oppenheimer initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday. They set an “outperform” rating and a $100.00 target price for the company. CIBC decreased their target price on shares of Stuart Olson from C$5.00 to C$4.00 in a research note on Tuesday. Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a “neutral” rating and a $336.00 target price for the company. Stifel Nicolaus set a $113.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday. Finally, Guggenheim started coverage on shares of resTORbio in a research note on Tuesday, June 4th. They set a “buy” rating and a $28.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and a consensus price target of $106.35.

Shares of NBIX traded up $0.39 during mid-day trading on Thursday, reaching $88.51. 565,146 shares of the company’s stock were exchanged, compared to its average volume of 859,070. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.61 and a current ratio of 8.79. The stock’s 50-day simple moving average is $84.54. Neurocrine Biosciences, Inc. has a 52-week low of $64.72 and a 52-week high of $126.98. The company has a market cap of $8.13 billion, a P/E ratio of 402.32 and a beta of 1.34.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The business had revenue of $138.40 million for the quarter, compared to analyst estimates of $136.77 million. During the same period in the prior year, the company earned ($0.47) earnings per share. The firm’s revenue for the quarter was up 94.7% on a year-over-year basis. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post -0.06 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: What Are Cryptocurrencies?

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.